{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:46:18Z","timestamp":1788349578104,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13300-025-01833-5","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:05:35Z","timestamp":1769497535000},"page":"431-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program"],"prefix":"10.1007","volume":"17","author":[{"given":"Eden","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Philis-Tsimikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Ilag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Threlkeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Levasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Gelsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"6","key":"1833_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2337\/db18-0856","volume":"68","author":"T Mezza","year":"2019","unstructured":"Mezza T, Cinti F, Cefalo CMA, Pontecorvi A, Kulkarni RN, Giaccari A. \u03b2-cell fate in human insulin resistance and type 2 diabetes: a perspective on islet plasticity. Diabetes. 2019;68(6):1121\u20139. https:\/\/doi.org\/10.2337\/db18-0856.","journal-title":"Diabetes"},{"issue":"12","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","volume":"24","author":"A Rubino","year":"2007","unstructured":"Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24(12):1412\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02279.x.","journal-title":"Diabet Med"},{"issue":"7","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.2337\/dc18-0116","volume":"41","author":"KM Pantalone","year":"2018","unstructured":"Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41(7):e113\u20134. https:\/\/doi.org\/10.2337\/dc18-0116.","journal-title":"Diabetes Care"},{"issue":"1","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2337\/diaclin.25.1.36","volume":"25","author":"MM Funnell","year":"2007","unstructured":"Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36\u20138. https:\/\/doi.org\/10.2337\/diaclin.25.1.36.","journal-title":"Clin Diabetes"},{"issue":"3","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/dom.13132","volume":"20","author":"D Russell-Jones","year":"2018","unstructured":"Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488\u201396. https:\/\/doi.org\/10.1111\/dom.13132.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1833_CR6","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s13300-024-01652-0","volume":"15","author":"FT Gelsey","year":"2024","unstructured":"Gelsey FT, Schapiro D, Kosa K, et al. Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin. Diabetes Ther. 2024;15(11):2367\u201379. https:\/\/doi.org\/10.1007\/s13300-024-01652-0.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/dom.14956","volume":"25","author":"T Heise","year":"2023","unstructured":"Heise T, Chien J, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023;25(4):1080\u201390. https:\/\/doi.org\/10.1111\/dom.14956.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00125-024-06158-9","volume":"67","author":"R Trevisan","year":"2024","unstructured":"Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. 2024;67(8):1480\u201392. https:\/\/doi.org\/10.1007\/s00125-024-06158-9.","journal-title":"Diabetologia"},{"issue":"3","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.122.001105","volume":"382","author":"JS Moyers","year":"2022","unstructured":"Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. J Pharmacol Exp Ther. 2022;382(3):346\u201355. https:\/\/doi.org\/10.1124\/jpet.122.001105.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10458","key":"1833_CR10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/s0140-6736(24)01804-x","volume":"404","author":"RM Bergenstal","year":"2024","unstructured":"Bergenstal RM, Weinstock RS, Mathieu C, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet. 2024;404(10458):1132\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(24)01804-x.","journal-title":"Lancet"},{"issue":"4","key":"1833_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2502796","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Bailey T, Connery L, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. 2025;393(4):325\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2502796.","journal-title":"N Engl J Med"},{"issue":"23","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","volume":"391","author":"C Wysham","year":"2024","unstructured":"Wysham C, Bajaj HS, Prato SD, et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med. 2024;391(23):2201\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2403953.","journal-title":"N Engl J Med"},{"issue":"10497","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/s0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, Dahl D, P\u00e9rez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290\u2013301. https:\/\/doi.org\/10.1016\/s0140-6736(25)01069-4.","journal-title":"Lancet"},{"issue":"10497","key":"1833_CR14","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/s0140-6736(25)01044-x","volume":"405","author":"A Philis-Tsimikas","year":"2025","unstructured":"Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2279\u201389. https:\/\/doi.org\/10.1016\/s0140-6736(25)01044-x.","journal-title":"Lancet"},{"issue":"1","key":"1833_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00219-4","volume":"4","author":"S Cruz Rivera","year":"2020","unstructured":"Cruz Rivera S, McMullan C, Jones L, Kyte D, Slade A, Calvert M. The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. J Patient Rep Outcomes. 2020;4(1):51. https:\/\/doi.org\/10.1186\/s41687-020-00219-4.","journal-title":"J Patient Rep Outcomes"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.diabres.2016.04.009","volume":"116","author":"M Reaney","year":"2016","unstructured":"Reaney M, Elash CA, Litcher-Kelly L. Patient reported outcomes (PROs) used in recent phase 3 trials for type 2 diabetes: a review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials. Diabetes Res Clin Pract. 2016;116:54\u201367. https:\/\/doi.org\/10.1016\/j.diabres.2016.04.009.","journal-title":"Diabetes Res Clin Pract"},{"key":"1833_CR17","doi-asserted-by":"publisher","unstructured":"Committee ADAPP. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes\u20142022. Diabetes Care. 2021;45(Supplement_1):S60\u2013S82. https:\/\/doi.org\/10.2337\/dc22-S005","DOI":"10.2337\/dc22-S005"},{"issue":"5","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008.","journal-title":"Value Health"},{"key":"1833_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-83","volume":"7","author":"M Brod","year":"2009","unstructured":"Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health Qual Life Outcomes. 2009;7:83. https:\/\/doi.org\/10.1186\/1477-7525-7-83.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s13300-023-01451-z","volume":"14","author":"KS Boye","year":"2023","unstructured":"Boye KS, Thieu VT, Sapin H, et al. Patient-reported outcomes in people with type\u00a02 diabetes receiving tirzepatide in the SURPASS clinical trial programme. Diabetes Ther. 2023;14(11):1833\u201352. https:\/\/doi.org\/10.1007\/s13300-023-01451-z.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1833_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00614-7","volume":"7","author":"KD Stewart","year":"2023","unstructured":"Stewart KD, Matza LS, Patel H, Boye KS. Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes. J Patient Rep Outcomes. 2023;7(1):89. https:\/\/doi.org\/10.1186\/s41687-023-00614-7.","journal-title":"J Patient Rep Outcomes"},{"key":"1833_CR22","unstructured":"Mandy van Reenen BJ, Elly S, Kristina SB, Mike H, Matthew Kennedy-Martin TK-M, Bernhard S, Kristina L. EuroQol Research Foundation. EQ-5D-5L User Guide, 2025. 2025. https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides. Accessed 26 September 2025"},{"issue":"5","key":"1833_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. <article-title update=\"added\">Eq-sd: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"1833_CR24","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1007\/978-3-031-17299-1_1774","volume-title":"Encyclopedia of quality of life and well-being research","author":"D Morley","year":"2023","unstructured":"Morley D, Jenkinson C. Medical Outcomes Study Short-Form 36-Item Questionnaire. In: Maggino F, editor. Encyclopedia of quality of life and well-being research. Springer International Publishing; 2023. p. 4285\u20138."},{"key":"1833_CR25","unstructured":"(FDA) USFaDA. Patient engagement in the design and conduct of medical device clinical studies. 2022:1\u201311. https:\/\/www.fda.gov\/media\/130917\/download. Accessed 30 July, 2025"},{"key":"1833_CR26","unstructured":"Agency EM. Engagement Framework: EMA and patients, consumers and their organisations. 2022:1\u20138. https:\/\/www.ema.europa.eu\/en\/documents\/other\/engagement-framework-european-medicines-agency-patients-consumers-their-organisations_en.pdf"},{"issue":"Suppl 1","key":"1833_CR27","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"ADA","year":"2024","unstructured":"ADA. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S158\u201378. https:\/\/doi.org\/10.2337\/dc24-S009.","journal-title":"Diabetes Care"},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.2147\/ppa.S367046","volume":"16","author":"TJ Sims","year":"2022","unstructured":"Sims TJ, Boye KS, Robinson S, Kennedy-Martin T. Treatment-related attributes of diabetes therapies and how people with type 2 diabetes report their impact on indicators of medication-taking behaviors. Patient Prefer Adherence. 2022;16:1919\u201339. https:\/\/doi.org\/10.2147\/ppa.S367046.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1833_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40200-019-00449-4","volume":"18","author":"M Toroski","year":"2019","unstructured":"Toroski M, Kebriaeezadeh A, Esteghamati A, Karyani AK, Abbasian H, Nikfar S. Patient and physician preferences for type 2 diabetes medications: a systematic review. J Diabetes Metab Disord. 2019;18(2):643\u201356. https:\/\/doi.org\/10.1007\/s40200-019-00449-4.","journal-title":"J Diabetes Metab Disord"},{"key":"1833_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.782964","volume":"9","author":"Y Huang","year":"2021","unstructured":"Huang Y, Huang Q, Xu A, Lu M, Xi X. Patient preferences for diabetes treatment among people with type 2 diabetes mellitus in China: a discrete choice experiment. Front Public Health. 2021;9:782964. https:\/\/doi.org\/10.3389\/fpubh.2021.782964.","journal-title":"Front Public Health"},{"key":"1833_CR31","unstructured":"Bradley C. Handbook of Psychology and Diabetes A Guide to Psychological Measurement in Diabetes Research and Practice. 1994"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01833-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:22:11Z","timestamp":1773822131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01833-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01833-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in Table 1.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eden Miller: has served as Abbott Ad board, Speaker, Research, Eli Lilly\/BI Ad board and Speaker, Insulet Ad board and Speakers Bureau Novo Nordisk Ad Board and Speaker. Harpreet S Bajaj: reports trial fees paid to his institution by Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ionis, Novartis, Novo Nordisk, and Pfizer. Julio Rosenstock: Research\/Grants Support Assigned to Velocity Clinical Research: Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Regeneron, Regor, Roche, Sanofi, Structure Therapeutics, and Terns; Advisory Boards, Consulting Fees\/Honorarium: Applied Therapeutics, Biomea Fusion, Corcept, Eli Lilly, Hanmi, Novo Nordisk, Oramed, Regeneron, Regor, Roche, Sanofi, Structure Therapeutics, and Terns. Athena Philis-Tsimikis: performs research and serves as an adviser on behalf of her employer for AbbVie, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, and Sanof. Richard M Bergenstal: has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, Amgen, Ascensia, CeQur, DexCom, Eli Lilly, Embecta, Hygieia, Insulet, Luna Health, Medtronic, Novo Nordisk, Roche Diabetes Care, Sequel, Tandem Diabetes Care, Sanofi, Vertex and Zealand. Richard M Bergenstal\u2019s: employer, non-profit HealthPartners Institute, contracts for his services and he receives no personal income from these activities. Michael B Davidson, Michael Case, Liza Ilag, Rebecca Threlkeld, Esther Levasseur, and Felicia Gelsey: are full-time employees and stockholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The QWINT-1 to -4 studies were approved by the ethics review board and conducted in accordance with local regulations, the Declaration of Helsinki, the Council of International Organizations of Medical Sciences International Ethical Guidelines, and Good Clinical Practice guidelines. All patients provided written informed consent. All necessary permission were obtained for use of PRO instruments in the original studies. This article is based on pre-specified analyses from previously conducted studies and does not include any new research involving human participants or animals by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}